Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141788 | 1.00 | CA1 (0.36) | CA1CA2CA4CA7F2 | |
| SCHEMBL14817044 | 1.00 | CA1 (0.36) | CA1CA2CA4CA7F2 | |
| Hydrochloric Acid SCHEMBL3370361 | 0.99 | CA1 (0.36) | CA1CA2CA4CA7F2 | |
| SCHEMBL30496307 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| SCHEMBL30607155 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| SCHEMBL12834785 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| SCHEMBL12860070 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| Hydrochloric Acid SCHEMBL2744323 | 0.85 | GRIK1 (0.35) | CYP2D6 | |
| SCHEMBL6769372 | 0.79 | P2RX3 (0.46) | PIM1 | |
| SCHEMBL6769375 | 0.79 | P2RX3 (0.46) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |